Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen
Patients initiating a CCR experienced greater time burden managing mCSPC and higher healthcare costs than those initiating an NCR. These findings support counseling expressing these differences in burden in mCSPC treatment decision-making conversations.
Authors
- Sabree Burbage
- Gordon Wong
- Carmine Rossi (ORCID: https://orcid.org/0000-0001-5801-6927)
- Jill Korsiak (ORCID: https://orcid.org/0000-0002-7509-4553)
- Arjun Gupta (ORCID: https://orcid.org/0000-0003-0875-4731)
- Ibrahim Khilfeh (ORCID: https://orcid.org/0000-0002-7677-2045)
- Alicia Katherine Morgans (ORCID: https://orcid.org/0000-0002-6563-4587)
- Daniel Sentana‐Lledo (ORCID: https://orcid.org/0000-0002-7318-0888)
- Dominic Pilon (ORCID: https://orcid.org/0000-0002-6093-7167)
- Lilián Díaz (ORCID: https://orcid.org/0009-0006-6397-0129)
Institutions
- Johnson & Johnson (United States) (US)
- Dana-Farber Cancer Institute (US)
- Group for Research in Decision Analysis (CA)
- University of Minnesota Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.3389/fonc.2025.1650378
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00